Skip to main content

Table 1 Clinical information and CSF characteristics of CIS patients included in the study

From: Validation of semaphorin 7A and ala-β-his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis

 

Cohort 1* - ELISA studies

Cohort 2** - proteomic studies

Characteristics

CIS → CIS

CIS → CDMS

P values

CIS → CIS

CIS → CDMS

P values

n

27

29

-

18

18

-

Age (years)a

28.1 (9.6)

27.4 (6.3)

0.724

31.7 (7.3)

30.2 (5.9)

0.308

Female/male (% female)

20/7 (74.1)

20/9 (69.0)

0.672

13/5 (72.2)

13/5 (72.2)

1

Follow-up time (years)a

8.2 (4.2)

8.6 (3.3)

0.819

6.1 (3.6)

8.8 (2.7)

0.098

Clinical presentation

      

Optic neuritis

15 (55.6)

8 (27.6)

0.206

9 (50.0)

3 (16.7)

0.152

Brainstem

4 (14.8)

7 (24.1)

 

2 (11.1)

5 (27.8)

 

Spinal

5 (18.5)

8 (27.6)

 

3 (16.7)

6 (33.3)

 

Others

3 (11.1)

6 (20.7)

 

4 (22.2)

4 (22.2)

 

CSF cellsb

0.5 (0-5.0)

2.0 (0-9.0)

0.337

0 (2.4-3.5)

4.0 (0-11.5)

0.059

Proteins (mg/dL)b

33.0 (24.0-43.0)

37.0 (26.8-57.3)

0.391

32.5 (23.7-41.5)

29.5 (24.0-51.8)

0.705

  1. *Cohort 1 was used for the determination of CSF and serum levels of apolipoprotein AI, apolipoprotein AIV, vitronectin, and plasminogen by ELISA. **Cohort 2 was used for the quantification of CSF levels of semaphorin 7A and ala-beta-his-dipeptidase by selected reaction monitoring (SRM). A total of 23 (63.9%) patients were present in both cohorts of patients. aData are expressed as mean (standard deviation). bData are expressed as median (interquartile range). P values were obtained following comparisons between CIS → CIS patients and CIS → CDMS patients by means of the chi-square test (gender and clinical presentation) and the Mann-Whitney U test (remaining variables). Proteins (mg/dL) refers to protein concentration in mg/dL. CDMS, clinically definite multiple sclerosis; CIS, clinically isolated syndromes, CSF, cerebrospinal fluid.